MICHAEL NESHEWAT: Open Payments
NPI 1174553770 · SOUTHGATE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,382 in 121 payments from 28 companies in 2025. Trend: 2023 $2,345 · 2024 $2,741 · 2025 $2,382
Food & beverage: $2,382
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $285 |
| PFIZER INC. | 10 | $275 |
| Lilly USA, LLC | 14 | $263 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $233 |
| Novo Nordisk Inc | 8 | $148 |
| Shionogi Inc | 5 | $143 |
| Otsuka America Pharmaceutical, Inc. | 7 | $135 |
| Novartis Pharmaceuticals Corporation | 6 | $95 |
| Aimmune Therapeutics, Inc. | 4 | $71 |
| Paratek Pharmaceuticals, Inc. | 4 | $71 |
Products named: CAPLYTA, REXULTI, VRAYLAR, Fetroja, ZAVZPRET, MOUNJARO, ZEPBOUND, LEQVIO.
Industry payments across MI — which companies pay providers there.
